Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$43.24
-3.49-7.47%
At close: -
$43.24
0.000.00%
After Hours: Apr 4, 4:00 PM EDT
Comments
Loading...
PTC Therapeutics Analyst Ratings and Price Targets | NASDAQ:PTCT | Benzinga
PTC Therapeutics Inc has a consensus price target of $54.95 based on the ratings of 20 analysts. The high is $113 issued by Cantor Fitzgerald on February 3, 2025. The low is $17 issued by Citigroup on October 27, 2023. The 3 most-recent analyst ratings were released by JP Morgan, JP Morgan, and B of A Securities on March 31, 2025, March 14, 2025, and March 11, 2025, respectively. With an average price target of $69.33 between JP Morgan, JP Morgan, and B of A Securities, there's an implied 60.35% upside for PTC Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
B of A Securities
Scotiabank
Morgan Stanley
RBC Capital
1calculated from analyst ratings
Analyst Ratings for PTC Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/31/2025 | Buy Now | 73.45% | JP Morgan | Eric Joseph43% | $78 → $75 | Maintains | Overweight | Get Alert |
| 03/14/2025 | Buy Now | 80.39% | JP Morgan | Eric Joseph43% | $72 → $78 | Maintains | Overweight | Get Alert |
| 03/11/2025 | Buy Now | 27.2% | B of A Securities | Tazeen Ahmad55% | $41 → $55 | Upgrade | Underperform → Neutral | Get Alert |
| 03/07/2025 | Buy Now | 27.2% | Scotiabank | Louise Chen54% | → $55 | Initiates | → Sector Perform | Get Alert |
| 03/07/2025 | Buy Now | 61.89% | Morgan Stanley | Jeffrey Hung52% | $67 → $70 | Assumes | → Overweight | Get Alert |
| 02/28/2025 | Buy Now | 66.51% | JP Morgan | Eric Joseph43% | $74 → $72 | Maintains | Overweight | Get Alert |
| 02/18/2025 | Buy Now | 45.7% | RBC Capital | Brian Abrahams50% | $60 → $63 | Maintains | Outperform | Get Alert |
| 02/12/2025 | Buy Now | 4.07% | Citigroup | David Lebowitz52% | $32 → $45 | Maintains | Sell | Get Alert |
| 02/03/2025 | Buy Now | 161.33% | Cantor Fitzgerald | Kristen Kluska66% | $76 → $113 | Maintains | Overweight | Get Alert |
| 01/15/2025 | Buy Now | 75.76% | Cantor Fitzgerald | Kristen Kluska66% | $80 → $76 | Maintains | Overweight | Get Alert |
| 12/13/2024 | Buy Now | 54.95% | Morgan Stanley | Jeffrey Hung52% | $45 → $67 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/04/2024 | Buy Now | -25.99% | Citigroup | David Lebowitz52% | $26 → $32 | Maintains | Sell | Get Alert |
| 12/04/2024 | Buy Now | -2.87% | Goldman Sachs | Paul Choi58% | $32 → $42 | Maintains | Sell | Get Alert |
| 12/03/2024 | Buy Now | 64.2% | UBS | Colin Bristow39% | $47 → $71 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 61.89% | Baird | Joel Beatty67% | $52 → $70 | Maintains | Outperform | Get Alert |
| 12/03/2024 | Buy Now | 29.51% | Barclays | Gena Wang50% | $45 → $56 | Maintains | Equal-Weight | Get Alert |
| 11/27/2024 | Buy Now | 20.26% | Baird | Joel Beatty67% | $48 → $52 | Maintains | Outperform | Get Alert |
| 11/26/2024 | Buy Now | 57.26% | Wells Fargo | Tiago Fauth41% | $56 → $68 | Maintains | Overweight | Get Alert |
| 11/19/2024 | Buy Now | 43.39% | JP Morgan | Eric Joseph43% | $51 → $62 | Maintains | Overweight | Get Alert |
| 11/14/2024 | Buy Now | 4.07% | Barclays | Gena Wang50% | $43 → $45 | Maintains | Equal-Weight | Get Alert |
| 11/11/2024 | Buy Now | -0.56% | Barclays | Gena Wang50% | $31 → $43 | Maintains | Equal-Weight | Get Alert |
| 11/08/2024 | Buy Now | 11.01% | Baird | Joel Beatty67% | $44 → $48 | Maintains | Outperform | Get Alert |
| 10/11/2024 | Buy Now | 4.07% | Morgan Stanley | Jeffrey Hung52% | $32 → $45 | Maintains | Equal-Weight | Get Alert |
| 10/08/2024 | Buy Now | 1.76% | Baird | Joel Beatty67% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 10/04/2024 | Buy Now | -21.37% | RBC Capital | Brian Abrahams50% | $32 → $34 | Maintains | Sector Perform | Get Alert |
| 09/20/2024 | Buy Now | 48.01% | Cantor Fitzgerald | Kristen Kluska66% | $64 → $64 | Reiterates | Overweight → Overweight | Get Alert |
| 09/17/2024 | Buy Now | 48.01% | Cantor Fitzgerald | Kristen Kluska66% | $64 → $64 | Reiterates | Overweight → Overweight | Get Alert |
| 09/04/2024 | Buy Now | 1.76% | Baird | Joel Beatty67% | → $44 | Initiates | → Outperform | Get Alert |
| 08/26/2024 | Buy Now | 8.7% | UBS | Colin Bristow39% | → $47 | Upgrade | Neutral → Buy | Get Alert |
| 08/21/2024 | Buy Now | 48.01% | Cantor Fitzgerald | Kristen Kluska66% | $64 → $64 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2024 | Buy Now | 48.01% | Cantor Fitzgerald | Kristen Kluska66% | $62 → $64 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | -28.31% | Barclays | Gena Wang50% | $25 → $31 | Maintains | Equal-Weight | Get Alert |
| 07/16/2024 | Buy Now | 43.39% | Cantor Fitzgerald | Kristen Kluska66% | $62 → $62 | Reiterates | Overweight → Overweight | Get Alert |
| 07/12/2024 | Buy Now | -25.99% | Morgan Stanley | Jeffrey Hung52% | $30 → $32 | Maintains | Equal-Weight | Get Alert |
| 07/01/2024 | Buy Now | 43.39% | Cantor Fitzgerald | Kristen Kluska66% | $52 → $62 | Maintains | Overweight | Get Alert |
| 06/21/2024 | Buy Now | -25.99% | B of A Securities | Tazeen Ahmad55% | $25 → $32 | Maintains | Underperform | Get Alert |
| 06/20/2024 | Buy Now | 22.57% | JP Morgan | Eric Joseph43% | $53 → $53 | Maintains | Overweight | Get Alert |
| 05/28/2024 | Buy Now | -25.99% | Goldman Sachs | Paul Choi58% | $18 → $32 | Maintains | Sell | Get Alert |
| 05/21/2024 | Buy Now | -39.87% | Citigroup | David Lebowitz52% | $18 → $26 | Maintains | Sell | Get Alert |
| 05/21/2024 | Buy Now | 22.57% | JP Morgan | Eric Joseph43% | $43 → $53 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | -25.99% | Goldman Sachs | Paul Choi58% | $18 → $32 | Maintains | Sell | Get Alert |
| 05/20/2024 | Buy Now | 6.38% | Jefferies | Kelly Shi38% | $35 → $46 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | -30.62% | Morgan Stanley | Jeffrey Hung52% | $28 → $30 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 04/12/2024 | Buy Now | 4.07% | Cantor Fitzgerald | Kristen Kluska66% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/20/2024 | Buy Now | -19.06% | Jefferies | Kelly Shi38% | $33 → $35 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | -35.25% | RBC Capital | Brian Abrahams50% | $28 → $28 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/01/2024 | Buy Now | 4.07% | Cantor Fitzgerald | Kristen Kluska66% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
| 03/01/2024 | Buy Now | -35.25% | RBC Capital | Brian Abrahams50% | $22 → $28 | Maintains | Sector Perform | Get Alert |
| 03/01/2024 | Buy Now | -30.62% | TD Cowen | Joseph Thome34% | $32 → $30 | Maintains | Market Perform | Get Alert |
| 01/26/2024 | Buy Now | -49.12% | RBC Capital | Brian Abrahams50% | $27 → $22 | Maintains | Sector Perform | Get Alert |
| 01/26/2024 | Buy Now | 4.07% | Cantor Fitzgerald | Kristen Kluska66% | $51 → $45 | Maintains | Overweight | Get Alert |
| 12/19/2023 | Buy Now | -35.25% | Morgan Stanley | Jeffrey Hung52% | → $28 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 12/18/2023 | Buy Now | 17.95% | Cantor Fitzgerald | Kristen Kluska66% | $51 → $51 | Reiterates | Overweight → Overweight | Get Alert |
| 12/18/2023 | Buy Now | -58.37% | Goldman Sachs | Paul Choi58% | $20 → $18 | Maintains | Sell | Get Alert |
| 11/20/2023 | Buy Now | 17.95% | Cantor Fitzgerald | Kristen Kluska66% | → $51 | Reiterates | Overweight → Overweight | Get Alert |
| 10/27/2023 | Buy Now | -35.25% | Morgan Stanley | Jeffrey Hung52% | $31 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -42.18% | Barclays | Gena Wang50% | $26 → $25 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | -60.68% | Citigroup | David Lebovitz64% | $29 → $17 | Downgrade | Neutral → Sell | Get Alert |
| 10/06/2023 | Buy Now | -42.18% | Truist Securities | Robyn Karnauskas55% | → $25 | Downgrade | Buy → Hold | Get Alert |
| 09/19/2023 | Buy Now | 4.07% | Truist Securities | Barry Jonas63% | → $45 | Reiterates | Buy → Buy | Get Alert |
| 09/19/2023 | Buy Now | -46.81% | B of A Securities | Tazeen Ahmad55% | $43 → $23 | Maintains | Underperform | Get Alert |
| 09/18/2023 | Buy Now | 4.07% | Truist Securities | Barry Jonas63% | $60 → $45 | Maintains | Buy | Get Alert |
| 09/18/2023 | Buy Now | -39.87% | Barclays | Gena Wang50% | $44 → $26 | Maintains | Equal-Weight | Get Alert |
| 09/18/2023 | Buy Now | -28.31% | Morgan Stanley | Jeffrey Hung52% | $47 → $31 | Maintains | Equal-Weight | Get Alert |
| 09/18/2023 | Buy Now | -49.12% | Goldman Sachs | Paul Choi58% | $35 → $22 | Maintains | Sell | Get Alert |
| 09/18/2023 | Buy Now | -39.87% | RBC Capital | Brian Abrahams50% | $49 → $26 | Maintains | Sector Perform | Get Alert |
| 09/18/2023 | Buy Now | -32.93% | Citigroup | David Lebovitz64% | $55 → $29 | Downgrade | Buy → Neutral | Get Alert |
| 09/18/2023 | Buy Now | — | Raymond James | Danielle Brill41% | — | Downgrade | Outperform → Underperform | Get Alert |
| 09/15/2023 | Buy Now | — | Raymond James | Danielle Brill41% | — | Downgrade | Outperform → Underperform | Get Alert |
| 08/16/2023 | Buy Now | 50.32% | Truist Securities | Barry Jonas63% | → $65 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 68.83% | Cantor Fitzgerald | Kristen Kluska66% | → $73 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 8.7% | Morgan Stanley | Jeffrey Hung52% | $47 → $47 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 1.76% | Barclays | Gena Wang50% | $48 → $44 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | 27.2% | Raymond James | Danielle Brill41% | $58 → $55 | Maintains | Outperform | Get Alert |
| 07/21/2023 | Buy Now | 68.83% | Cantor Fitzgerald | Kristen Kluska66% | → $73 | Reiterates | Overweight → Overweight | Get Alert |
| 07/20/2023 | Buy Now | 13.32% | RBC Capital | Brian Abrahams50% | → $49 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 07/20/2023 | Buy Now | 68.83% | Cantor Fitzgerald | Kristen Kluska66% | → $73 | Reiterates | Overweight → Overweight | Get Alert |
| 07/20/2023 | Buy Now | 15.63% | Credit Suisse | Judah Frommer65% | → $50 | Reiterates | Neutral → Neutral | Get Alert |
| 07/11/2023 | Buy Now | 8.7% | Morgan Stanley | Jeffrey Hung52% | $50 → $47 | Maintains | Equal-Weight | Get Alert |
| 06/30/2023 | Buy Now | 68.83% | Cantor Fitzgerald | Kristen Kluska66% | $75 → $73 | Maintains | Overweight | Get Alert |
| 05/24/2023 | Buy Now | -2.87% | B of A Securities | Tazeen Ahmad55% | → $42 | Maintains | Underperform | Get Alert |
| 05/24/2023 | Buy Now | 20.26% | RBC Capital | Brian Abrahams50% | → $52 | Maintains | Sector Perform | Get Alert |
| 05/24/2023 | Buy Now | 15.63% | Credit Suisse | Judah Frommer65% | $55 → $50 | Maintains | Neutral | Get Alert |
| 05/24/2023 | Buy Now | -7.49% | TD Cowen | Joseph Thome34% | $47 → $40 | Maintains | Market Perform | Get Alert |
| 05/24/2023 | Buy Now | 45.7% | Citigroup | David Lebovitz64% | $70 → $63 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | 11.01% | Barclays | Gena Wang50% | $57 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/18/2023 | Buy Now | -0.56% | B of A Securities | Tazeen Ahmad55% | $36 → $43 | Maintains | Underperform | Get Alert |
| 05/18/2023 | Buy Now | 61.89% | Citigroup | David Lebovitz64% | $67 → $70 | Maintains | Buy | Get Alert |
| 05/18/2023 | Buy Now | 31.82% | Barclays | Gena Wang50% | $47 → $57 | Maintains | Equal-Weight | Get Alert |
| 05/18/2023 | Buy Now | -14.43% | Goldman Sachs | Paul Choi58% | $35 → $37 | Maintains | Sell | Get Alert |
| 05/08/2023 | Buy Now | 48.01% | JP Morgan | Eric Joseph43% | $57 → $64 | Maintains | Overweight | Get Alert |
| 05/01/2023 | Buy Now | 34.14% | Raymond James | Danielle Brill41% | $55 → $58 | Maintains | Outperform | Get Alert |
| 04/28/2023 | Buy Now | 17.95% | Credit Suisse | Judah Frommer65% | $48 → $51 | Maintains | Neutral | Get Alert |
| 04/28/2023 | Buy Now | 54.95% | Citigroup | David Lebovitz64% | $61 → $67 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 50.32% | Truist Securities | Barry Jonas63% | $60 → $65 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 11.01% | SVB Leerink | Joseph Schwartz65% | → $48 | Initiates | → Market Perform | Get Alert |
| 02/23/2023 | Buy Now | 27.2% | Raymond James | Danielle Brill41% | $60 → $55 | Maintains | Outperform | Get Alert |
| 02/22/2023 | Buy Now | -16.74% | B of A Securities | Tazeen Ahmad55% | → $36 | Maintains | Underperform | Get Alert |
| 02/22/2023 | Buy Now | 52.64% | Cantor Fitzgerald | Kristen Kluska66% | $68 → $66 | Maintains | Overweight | Get Alert |
| 02/22/2023 | Buy Now | 11.01% | Credit Suisse | Judah Frommer65% | → $48 | Reiterates | → Neutral | Get Alert |
FAQ
What is the target price for PTC Therapeutics (PTCT) stock?
The latest price target for PTC Therapeutics (NASDAQ:PTCT) was reported by JP Morgan on March 31, 2025. The analyst firm set a price target for $75.00 expecting PTCT to rise to within 12 months (a possible 73.45% upside). 44 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for PTC Therapeutics (PTCT)?
The latest analyst rating for PTC Therapeutics (NASDAQ:PTCT) was provided by JP Morgan, and PTC Therapeutics maintained their overweight rating.
When was the last upgrade for PTC Therapeutics (PTCT)?
The last upgrade for PTC Therapeutics Inc happened on March 11, 2025 when B of A Securities raised their price target to $55. B of A Securities previously had an underperform for PTC Therapeutics Inc.
When was the last downgrade for PTC Therapeutics (PTCT)?
The last downgrade for PTC Therapeutics Inc happened on December 19, 2023 when Morgan Stanley changed their price target from N/A to $28 for PTC Therapeutics Inc.
When is the next analyst rating going to be posted or updated for PTC Therapeutics (PTCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on March 31, 2025 so you should expect the next rating to be made available sometime around March 31, 2026.
Is the Analyst Rating PTC Therapeutics (PTCT) correct?
While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a maintained with a price target of $78.00 to $75.00. The current price PTC Therapeutics (PTCT) is trading at is $43.24, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.